Compare EQIX & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EQIX | SNY |
|---|---|---|
| Founded | 1998 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.7B | 107.3B |
| IPO Year | 2000 | N/A |
| Metric | EQIX | SNY |
|---|---|---|
| Price | $1,002.10 | $47.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 5 |
| Target Price | ★ $1,001.81 | $58.00 |
| AVG Volume (30 Days) | 515.2K | ★ 3.2M |
| Earning Date | 04-29-2026 | 04-23-2026 |
| Dividend Yield | 2.06% | ★ 3.34% |
| EPS Growth | ★ 61.88 | N/A |
| EPS | ★ 13.76 | N/A |
| Revenue | ★ $5,998,545,000.00 | N/A |
| Revenue This Year | $12.32 | $3.86 |
| Revenue Next Year | $8.85 | $5.64 |
| P/E Ratio | $72.66 | ★ $6.14 |
| Revenue Growth | ★ 7.85 | N/A |
| 52 Week Low | $701.41 | $43.32 |
| 52 Week High | $1,006.56 | $55.73 |
| Indicator | EQIX | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 69.74 | 62.50 |
| Support Level | $759.85 | $47.30 |
| Resistance Level | N/A | $48.97 |
| Average True Range (ATR) | 18.10 | 0.77 |
| MACD | -0.94 | 0.47 |
| Stochastic Oscillator | 88.40 | 90.85 |
Equinix is one of the leading providers of cloud- and carrier-neutral data centers, offering colocation and interconnection services to hyperscalers and businesses. Equinix operates 270 properties in 77 metropolitan areas across 36 countries, serving over 10,000 customers. About 70% of Equinix's revenue comes from renting physical space, which allows hyperscalers and other clients to store servers, data storage, and networking equipment. The other 30% of revenue is generated primarily through interconnection services (20%) and other managed services (10%).
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.